Zhongguo shuxue zazhi (Aug 2022)

Research progress in clinical application of lymphoplasmapheresis in immune-related diseases

  • Shipeng KE,
  • Xu LI,
  • Ling YU,
  • Ting HUANG,
  • Huixia ZHANG,
  • Fen HU,
  • Shubiao ZOU,
  • Meiying RAO,
  • Simei CHEN

DOI
https://doi.org/10.13303/j.cjbt.issn.1004-549x.2022.08.026
Journal volume & issue
Vol. 35, no. 8
pp. 882 – 886

Abstract

Read online

Lymphoplasmapheresis(LPE) is a combination of plasma exchange and lymphocyte separation technology. It can not only remove autoimmune antibodies, but also remove the immune active cells producing these antibodies. At the same time, it can inhibit cellular and humoral immune responses, and improve the efficiency and reliability of treatment. This technology is safe, reliable, and easy to operate. In recent years, it has been widely used in the treatment of various autoimmune diseases and the suppression of immune rejection after organ transplantation, especially in the treatment of critically ill patients. This paper summarizes the clinical application status of LPE in immune-related diseases at home and abroad, analyzes the problems existing in the clinical promotion of LPE, and makes a prospect of its application value.

Keywords